Aegerion Pharmaceuticals Company Profile (NASDAQ:AEGR)

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AEGR
  • CUSIP: 00767E10
Key Metrics:
  • Previous Close: $1.74
  • 50 Day Moving Average: $1.54
  • 200 Day Moving Average: $2.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.80
  • P/E Growth: -0.03
  • Market Cap: $46.34M
  • Outstanding Shares: 29,514,000
  • Beta: 0.6
Additional Links:
Companies Related to Aegerion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Aegerion Pharmaceuticals (NASDAQ:AEGR) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $14.83 (752.49% upside)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateFirmActionRatingPrice TargetDetails
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00View Rating Details
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details
2/12/2016Bank of America Corp.DowngradeNeutral -> Underperform$6.00View Rating Details
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00View Rating Details
11/11/2015JPMorgan Chase & Co.Reiterated RatingNeutral$24.00View Rating Details
11/10/2015Jefferies GroupLower Price TargetBuy$26.00 -> $16.00View Rating Details
5/26/2015Needham & Company LLCReiterated RatingHoldView Rating Details
10/31/2014Deutsche Bank AGDowngradeBuy -> Hold$58.00 -> $26.00View Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q2($0.38)($0.72)$35.50 million$44.50 millionViewN/AView Earnings Details
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details
8/5/2015Q2($0.28)$0.23$58.98 million$64.20 millionViewN/AView Earnings Details
5/4/2015Q414($0.26)$0.06$59.30 millionViewN/AView Earnings Details
2/26/2015Q4$0.08$0.11$49.18 million$51.71 millionViewN/AView Earnings Details
10/30/2014Q314($0.14)($0.20)$48.60 million$43.70 millionViewN/AView Earnings Details
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details
5/6/2014Q1($0.35)($0.25)$33.58 million$27.00 millionViewListenView Earnings Details
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Current Year EPS Consensus Estimate: $-2.3 EPS
Next Year EPS Consensus Estimate: $-0.3 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)$0.09($0.34)
Q2 20163($0.73)($0.01)($0.44)
Q3 20163($0.73)$0.15($0.37)
Q4 20163($0.78)($0.04)($0.42)
(Data provided by Zacks Investment Research)


Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Aegerion Pharmaceuticals (NASDAQ:AEGR)
News IconAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Analyst Opinion - The Independent Republic (NASDAQ:AEGR) - August 24 at 3:22 PM
News IconIs it Time to Buy Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? The Consensus Is In - Post News (NASDAQ:AEGR) - August 22 at 8:07 AM logoWill Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Hit $2 Price Target? - Investor Newswire (NASDAQ:AEGR) - August 20 at 3:22 PM logoAEGERION PHARMACEUTICALS, INC. Financials (NASDAQ:AEGR) - August 19 at 3:43 PM logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aegerion Pharmaceuticals, Inc. (AEGR) (NASDAQ:AEGR) - August 17 at 3:21 PM logoETF’s with exposure to Aegerion Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:AEGR) - August 12 at 3:24 PM logoAegerion Pharmaceuticals, Inc. :AEGR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:AEGR) - August 11 at 12:33 PM logoAegerion Pharmaceuticals Announces Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:AEGR) - August 10 at 3:40 PM logoAegerion reports 2Q loss (NASDAQ:AEGR) - August 9 at 9:23 PM logoBRIEF-Aegerion Pharmaceuticals announces Q2 2016 financial results (NASDAQ:AEGR) - August 9 at 5:37 PM logoAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AEGR) - August 8 at 3:20 PM logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Updated Price Targets - FTSE News (NASDAQ:AEGR) - August 1 at 8:06 AM logoAegerion Pharmaceuticals Inc. (AEGR) Drops 5.16% on July 28 ... - (NASDAQ:AEGR) - July 30 at 3:25 PM logoAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.64% on July 27 - (NASDAQ:AEGR) - July 28 at 11:57 AM
News IconEquity Roundup: Stock Performance Focus on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Press Telegraph (NASDAQ:AEGR) - July 23 at 3:20 PM
News IconStock Displaying Signs of a Downtrend: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Press Telegraph (NASDAQ:AEGR) - July 23 at 3:20 PM logoIs $2 Price Target Attainable For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? - Investor Newswire (NASDAQ:AEGR) - July 23 at 3:20 PM logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Decreased -2.61%: Ligand Pharmaceuticals Incorporated (NASDAQ ... - KC Register (NASDAQ:AEGR) - July 22 at 3:19 PM
News IconAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:AEGR) - July 21 at 3:20 PM logoAegerion Pharma (AEGR) to Reduce Workforce as Part of Cost Reduction Plans - (NASDAQ:AEGR) - July 21 at 3:20 PM logoAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with (NASDAQ:AEGR) - July 20 at 4:09 PM logo4:04 pm Aegerion Pharma intends to withdraw lomitapide from the EU; is reducing ~13% of its global workforce (NASDAQ:AEGR) - July 20 at 4:04 PM logoAegerion Pharmaceuticals Announces Cost Reduction Plans (NASDAQ:AEGR) - July 20 at 4:02 PM
News IconHow Analysts Rated Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Last Week? - Consumer Eagle (NASDAQ:AEGR) - July 19 at 3:20 PM
News IconInvestor Watch: Volatility Recap on Shares of: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily (NASDAQ:AEGR) - July 18 at 3:19 PM
News IconHC Stocks Momentum: StemCells Inc (NASDAQ:STEM), Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - share market updates (press release) (NASDAQ:AEGR) - July 18 at 8:06 AM
News IconAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:AEGR) - July 18 at 8:06 AM
News IconShares Moving Down on the Week: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily (NASDAQ:AEGR) - July 17 at 8:06 AM logoStrong Sell Calls For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) At 0 - Investor Newswire (NASDAQ:AEGR) - July 17 at 8:06 AM
News IconAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Sellers Covered 4.56% of Their Shorts - Consumer Eagle (NASDAQ:AEGR) - July 16 at 3:20 PM
News IconEye on Stock Volatility for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily (NASDAQ:AEGR) - July 14 at 3:21 PM
News IconAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Short Interest Decreased By 4.56% - Consumer Eagle (NASDAQ:AEGR) - July 13 at 3:19 PM logoBest Stocks: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Boston Scientific Corporation (NYSE:BSX), Retrophin ... - KC Register (NASDAQ:AEGR) - July 12 at 3:23 PM logoEarnings Surprise in Focus: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Investor Newswire (NASDAQ:AEGR) - July 10 at 3:19 PM
News IconAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Sellers Covered 4.56% of Their Shorts - Press Telegraph (NASDAQ:AEGR) - July 10 at 8:05 AM logoIs $2 Within Reach For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? - Investor Newswire (NASDAQ:AEGR) - July 10 at 8:05 AM logoAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.14% on July 07 - (NASDAQ:AEGR) - July 8 at 3:21 PM
News IconHeightened Volatility Check on: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily (NASDAQ:AEGR) - July 7 at 3:21 PM
News IconIncreased Volatility Watch for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily (NASDAQ:AEGR) - July 6 at 3:21 PM logoAegerion Pharmaceuticals Inc. (AEGR) Jumps 6.04% on July 04 - (NASDAQ:AEGR) - July 6 at 8:07 AM logoAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:AEGR) - July 5 at 4:03 PM
News IconAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Sellers Covered 4.56% of Their Shorts - Engelwood Daily (NASDAQ:AEGR) - July 4 at 3:18 PM
News IconWere Analysts Bearish Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) This Week? - Press Telegraph (NASDAQ:AEGR) - July 4 at 8:06 AM logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:AEGR) - July 4 at 8:06 AM logoAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Expected to Reach Highs Of $6 - Investor Newswire (NASDAQ:AEGR) - July 2 at 3:18 PM logoAegerion Pharmaceuticals Inc. (AEGR) Jumps 6.04% on July 01 - (NASDAQ:AEGR) - July 1 at 8:35 PM
News IconShares Headed Up in Session: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Telanagana Press (NASDAQ:AEGR) - July 1 at 3:21 PM logoNew Broker Ratings For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - FTSE News (NASDAQ:AEGR) - July 1 at 11:19 AM
News IconUpdate on Stock Volatility for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily (NASDAQ:AEGR) - June 30 at 3:21 PM
News IconCovering the Bases on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Where is the Stock Going? - Press Telegraph (NASDAQ:AEGR) - June 28 at 3:33 PM


Aegerion Pharmaceuticals (NASDAQ:AEGR) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff